Compound ID | 1228
Synonym(s): NAB741
Class: Polymyxin
| Details of activity: | Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and and disrupts the physical integrity of the phospholipid bilayer of the inner membrane, and possibly additional modes of action. |
| Combined with other compounds: | Yes |
| Description: | Potentiates the activity of rifampin, clarithromycin, azithromycin, mupirocin, fusidic acid and vancomycin against E. coli, K. pneumoniae and A. baumannii but not P. aeruginosa. |
| Institute where first reported: | Northern Antibiotics, Spero Therapeutics |
| Highest development stage: | Phase 1 |
| Development status: | Withdrawn |
| Reason dropped: | Replaced by SPR206; develoiped instead as an antibiotic adjuvant |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/53323381 |
| Guide to Pharmacology: | SPR741 |
| Citations: |
|